Alector (ALEC) vs SAB Biotherapeutics (SABS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SAB Biotherapeutics (SABS) has outperformed Alector (ALEC) over the past year, gaining 23.5% versus a loss of 34.4%. Over five years, ALEC leads with a -91.3% price change compared with -97.1% for SABS. SAB Biotherapeutics is the larger company by market cap ($267.0 million vs $235.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | SABS |
|---|---|---|
| Share price | $2.11 | $2.94 |
| Market cap | $235.70M | $267.04M |
| 1-day change | +4.50% | +1.56% |
| YTD return | +29.49% | -22.73% |
| 1-year return | -34.42% | +23.50% |
| 5-year return | -91.33% | -97.14% |
| EPS (TTM) | $-1.09 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.40 | $5.15 |
| 52-week low | $1.09 | $2.10 |
| Distance from 52-week high | -37.91% | -43.01% |
| Analyst consensus | hold | none |
| Avg. price target upside | +56.33% | +296.59% |
| Average volume | 2.86M | 497.66K |
| Shares outstanding | 111.66M | 90.99M |
| Employees | 103 | 86 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SABS has outperformed ALEC by 57.9 percentage points over the past year.
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees
ALEC vs SABS FAQ
Which is bigger, Alector or SAB Biotherapeutics?
SAB Biotherapeutics (SABS) is larger, with a market capitalization of $267.04M compared with $235.70M for Alector (ALEC).
Which stock has performed better over the past year, ALEC or SABS?
SABS returned +23.50% over the past 12 months, compared with -34.42% for ALEC (price return, excluding dividends). Past performance does not predict future results.
Are Alector and SAB Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.